AAA
AUTL

Affinity Asset Advisors’s Autolus Therapeutics AUTL Stock Holding History

Affinity Asset Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,750,000
Closed -$2.85M – 98
2025
Q3 		$2.85M Sell
1,750,000
-1,295,000
-43% -$2.53M 0.25% 66
2025
Q2 		$6.94M Hold
3,045,000
– – 0.95% 33
2025
Q1 		$4.72M Sell
3,045,000
-1,455,000
-32% -$2.95M 0.45% 46
2024
Q4 		$10.6M Hold
4,500,000
– – 1.42% 25
2024
Q3 		$16.3M Buy
4,500,000
+200,000
+5% +$798K 2.23% 14
2024
Q2 		$15M Buy
4,300,000
+925,000
+27% +$3.99M 1.72% 17
2024
Q1 		$21.5M Buy
3,375,000
+1,824,592
+118% +$11.4M 2.67% 8
2023
Q4 		$9.98M Sell
1,550,408
-442,058
-22% -$1.69M 1.82% 20
2023
Q3 		$4.64M Buy
1,992,466
+403,449
+25% +$1.15M 1.31% 26
2023
Q2 		$3.78M Buy
+1,589,017
New +$3.77M 1.32% 25

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Affinity Asset Advisors's AUTL Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Autolus Therapeutics (AUTL) in Q4 2025, closing a stake of 1,750,000 shares — an estimated $2.85M sold.

Affinity Asset Advisors first reported a position in AUTL in Q2 2023 and held it in 10 quarters. The position peaked at $21.5M in Q1 2024. 89 funds tracked by Wall St. Rank hold AUTL as of Q4 2025.

  • Affinity Asset Advisors reported no remaining Autolus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 1,750,000 Autolus Therapeutics shares in Q4 2025, an estimated $2.85M.
  • Affinity Asset Advisors first reported a position in Autolus Therapeutics in Q2 2023 and held it in 10 quarters.
  • Affinity Asset Advisors's Autolus Therapeutics position peaked at $21.5M in Q1 2024.
  • 89 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.